Amplimed Pancreatic Cancer Protocol for Phase I Trial
By Webmaster
Posted on 12/25/2004
A phase I Trial of Imexon Injection (Amplimexon) plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma
• STATUS – open and accruing
• ELIGIBILITY:
INCLUSION – histologically or cytologically confirmed, advanced previously untreated pancreatic adenocarcinoma; adequate organ function; status post radiation or surgery for 2 weeks
EXCLUSION – previous therapy for metastatic disease; concurrent malignancy; known or symptomatic brain mets
This study is for patients that are newly diagnosed or who have not been previously treated. If you have any questions or are interested in participating in the clinical trial – please contact Allison Kaplan at (310) 633-8400.
